Enhancing the Bystander Effect of Antibody-Drug Conjugates by Using a Novel Caspase-3 Cleavable Peptide Linker to Overcome Tumor Heterogeneity
A DEVD Linker Enables Dual Intracellular and Extracellular Payload Release, Sustaining Bystander Killing in Heterogeneous Tumors Even After Antigen-Positive Cell Depletion.
Tumor heterogeneity, characterized by varying antigen expression levels within a tumor, poses a significant challenge to the efficacy of antibody-drug conjugates (ADCs).
